Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Information

Schedule of research and development costs

	Three Months Ended		Three Months Ended
	March 31, 2025		March 31, 2024
	(In thousands)
Barzolvolimab/Anti-KIT Program	$	39,703	$	23,778
CDX-622		5,451		3,421
Other Programs (a)		7,460		4,462
Total R&D Expense	$	52,614	$	31,661

(a) Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs.

	Three Months Ended		Three Months Ended
	March 31, 2025		March 31, 2024
		(In thousands)
Personnel	$	13,600	$	11,440
Laboratory supplies		2,168		1,308
Facility		1,406		1,286
Product development (b)		32,166		15,525
Other expenses (c)		3,274		2,102
Total R&D expense	$	52,614	$	31,661

(b) Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing.

(c) Other expenses primarily include research and development consulting, insurance, licensing and software expenses.